CY1107729T1 - Φαρμακευτικες συνθεσεις - Google Patents

Φαρμακευτικες συνθεσεις

Info

Publication number
CY1107729T1
CY1107729T1 CY20071101157T CY071101157T CY1107729T1 CY 1107729 T1 CY1107729 T1 CY 1107729T1 CY 20071101157 T CY20071101157 T CY 20071101157T CY 071101157 T CY071101157 T CY 071101157T CY 1107729 T1 CY1107729 T1 CY 1107729T1
Authority
CY
Cyprus
Prior art keywords
disorder
pharmaceutical compositions
composition
fluoroanilino
cyclooxygenase
Prior art date
Application number
CY20071101157T
Other languages
Greek (el)
English (en)
Inventor
Simon David Bateman
Alberto Gimona
Jurij Holinej
Jasper Huels
Sumedha Jayawardene
Argeris Jerry Karabelas
Maha Y Khaled
Anees Abdulquadar Karnachi
Lochlainn Eimear Mairin Nic
Richard Macerata
Victor Sloan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1107729T1 publication Critical patent/CY1107729T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20071101157T 2000-09-11 2007-09-07 Φαρμακευτικες συνθεσεις CY1107729T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23165500P 2000-09-11 2000-09-11
US23226100P 2000-09-14 2000-09-14
EP01982270A EP1331972B1 (en) 2000-09-11 2001-09-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CY1107729T1 true CY1107729T1 (el) 2013-04-18

Family

ID=26925315

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101157T CY1107729T1 (el) 2000-09-11 2007-09-07 Φαρμακευτικες συνθεσεις

Country Status (28)

Country Link
US (2) US20020061932A1 (enExample)
EP (1) EP1331972B1 (enExample)
JP (2) JP2004527458A (enExample)
KR (1) KR20030036730A (enExample)
CN (1) CN100490797C (enExample)
AR (1) AR030630A1 (enExample)
AT (1) ATE366128T1 (enExample)
AU (2) AU2002213900C1 (enExample)
BR (1) BR0113809A (enExample)
CA (1) CA2416771C (enExample)
CY (1) CY1107729T1 (enExample)
CZ (1) CZ2003673A3 (enExample)
DE (1) DE60129238T2 (enExample)
DK (1) DK1331972T3 (enExample)
ES (1) ES2290181T3 (enExample)
HU (1) HUP0301128A3 (enExample)
IL (2) IL154238A0 (enExample)
MX (1) MXPA03002105A (enExample)
MY (1) MY126117A (enExample)
NO (1) NO20031095D0 (enExample)
NZ (1) NZ524785A (enExample)
PE (1) PE20020351A1 (enExample)
PL (1) PL359721A1 (enExample)
PT (1) PT1331972E (enExample)
RU (1) RU2316324C2 (enExample)
SI (1) SI1331972T1 (enExample)
SK (1) SK2902003A3 (enExample)
WO (1) WO2002020090A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica
GB0201520D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Pharmaceutical uses
CA2476744A1 (en) * 2002-03-07 2003-09-12 Novartis Ag Solid pharmaceutical compositions comprising lumiracoxib
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AR042206A1 (es) 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
TWI327913B (en) * 2003-03-12 2010-08-01 Novartis Ag Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
RU2423979C2 (ru) * 2005-06-17 2011-07-20 АФТ Фармасьютикалз Лимитед Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
WO2008086537A2 (en) * 2007-01-11 2008-07-17 Analog Devices, Inc. Aluminum based bonding of semiconductor wafers
AU2009282901A1 (en) * 2008-08-22 2010-02-25 Novartis Ag Use of a COX-2 inhibitor for the treatment of a COX-2 dependent disorder in a patient not carrying HLA alleles associated with hepatotoxicity
US8227451B2 (en) 2008-11-12 2012-07-24 Auspex Pharmaceuticals Phenylacetic acid inhibitors of cyclooxygenase
CN103773596B (zh) * 2013-12-31 2016-05-18 上海复力生物医药科技有限公司 磷虾油的制备方法
KR102557900B1 (ko) 2016-09-07 2023-07-19 트러스티즈 오브 터프츠 칼리지 면역-dash 억제제와 pge2 길항제를 이용한 병행 요법
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0701449T3 (da) * 1993-06-08 2003-11-10 Novartis Ag Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
EP0910368A1 (en) * 1996-05-17 1999-04-28 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
AR036312A1 (es) * 2001-08-31 2004-08-25 Novartis Ag Composicion farmaceutica

Also Published As

Publication number Publication date
SI1331972T1 (sl) 2007-12-31
CA2416771A1 (en) 2002-03-14
WO2002020090A9 (en) 2003-10-30
WO2002020090A3 (en) 2003-05-30
CZ2003673A3 (cs) 2003-06-18
HUP0301128A3 (en) 2005-04-28
AU2002213900B2 (en) 2006-02-16
US20040186179A1 (en) 2004-09-23
PT1331972E (pt) 2007-10-16
CN1455691A (zh) 2003-11-12
CA2416771C (en) 2010-11-02
MXPA03002105A (es) 2003-06-19
US20020061932A1 (en) 2002-05-23
AR030630A1 (es) 2003-08-27
AU2002213900C1 (en) 2006-07-27
EP1331972B1 (en) 2007-07-04
DE60129238T2 (de) 2008-03-06
MY126117A (en) 2006-09-29
CN100490797C (zh) 2009-05-27
IL154238A (en) 2008-11-26
WO2002020090A2 (en) 2002-03-14
JP2011144194A (ja) 2011-07-28
DE60129238D1 (de) 2007-08-16
RU2316324C2 (ru) 2008-02-10
JP2004527458A (ja) 2004-09-09
NZ524785A (en) 2005-10-28
ES2290181T3 (es) 2008-02-16
AU1390002A (en) 2002-03-22
IL154238A0 (en) 2003-09-17
EP1331972A2 (en) 2003-08-06
DK1331972T3 (da) 2007-11-05
HUP0301128A2 (hu) 2003-10-28
KR20030036730A (ko) 2003-05-09
PE20020351A1 (es) 2002-06-14
PL359721A1 (en) 2004-09-06
NO20031095L (no) 2003-03-10
SK2902003A3 (en) 2003-10-07
NO20031095D0 (no) 2003-03-10
BR0113809A (pt) 2003-07-29
ATE366128T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
ES2051641A1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
WO2002011764A3 (en) PHARMACEUTICAL COMPOSITIONS
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
SV1999000194A (es) Preparado farmaceuticio de moxifloxacina ref. lea 33327-sv
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
DK1311256T3 (da) Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
BR0115424A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, para prevenir a doença de alzheimer, e para inibir o progresso da doença de alzheimer, processos para preparar o composto, e para preparar lactamas, e, uso do composto
NO20052908L (no) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
CY1106137T1 (el) Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
BR9507381A (pt) Composto uso de um composto processo para o tratamento de um manifero composição famacèutica e processo para a preparação de compostos
TR200101245T2 (tr) N-arilsulfonil-aminoasit-omega-amidler
BR0104358A (pt) Formulações de taxana tendo solubilidade aperfeiçoada
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.